Which Segment Did You Bet On?
Executive Summary
Stockholders didn't do well with most Big Cap indices, but they did a lot than with Big Pharma-which lost $270 billion of market value over five years. Not that life sciences in general wasn't a good place to park your savings. According to our market cap analysis of health care industry segments, you would have done extremely well to have invested in medical devices-the best performing sector in our universe.
You may also be interested in...
The Buzz at JP Morgan--Biopharma: New Models Wanted
Perhaps the loudest message from the biopharmaceutical side of the JP Morgan conference was: "Change the Big Pharma model." The theme was pervasive-in discussions of the most interesting products; among the biotechs; indeed in the Big Pharma presentations themselves.
The Buzz at JP Morgan--Devices: No Longer the Conference Stepchild
Over the past five years, big cap device companies have been some of the strongest performers among all life science stocks, and this year's conference represented something of a renaissance of device companies. However, most interesting wasn't so much the revival of interest in device stocks itself, but the message that device companies sent and that investors are embracing: "Forget about the hype; slow and steady wins the race."
The Buzz at JP Morgan--Devices: No Longer the Conference Stepchild
Over the past five years, big cap device companies have been some of the strongest performers among all life science stocks, and this year's conference represented something of a renaissance of device companies. However, most interesting wasn't so much the revival of interest in device stocks itself, but the message that device companies sent and that investors are embracing: "Forget about the hype; slow and steady wins the race."